Exelixis (EXEL) : 3 investment research analysts covering Exelixis (EXEL) have an average price target of $8.33 for the near short term. The highest target price given by the Brokerage Firm to the stock is $10 and the lowest target is $5 for the short term. Analysts expect the variance to be within $2.89 of the average price.
Exelixis (EXEL) has shown a rise of 1.8% or 871,226 shares in the short positions. The bets have increased to 48,801,977 shares on June 30,2016 from 47,930,751 shares on June 15,2016. With respect to the floated shares, the shorts are 23.4%. The days to cover are calculated to be 6, using the standard per day volume of 7,766,518 shares. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 12th.
Also, Stifel Nicolaus upgrades its view on Exelixis (NASDAQ:EXEL) according to the research report released by the firm to its investors. The shares have now been rated Buy by the stock experts at the ratings house. Earlier, the shares had a rating of Hold. The rating by the firm was issued on April 4, 2016.
Exelixis (NASDAQ:EXEL): stock turned positive on Thursday. Though the stock opened at $8.11, the bulls momentum made the stock top out at $8.26 level for the day. The stock recorded a low of $7.97 and closed the trading day at $8.22, in the green by 2.24%. The total traded volume for the day was 6,265,979. The stock had closed at $8.04 in the previous days trading.
Exelixis Inc. is a biopharmaceutical company. The Company is engaged in developing small molecule therapies for the treatment of cancer. The Company is focusing on resources development and commercialization of COMETRIQ (cabozantinib) for the treatment of progressive, metastatic medullary thyroid cancer (MTC) in the United States. The Companys other programs include metastatic renal cell carcinoma (mRCC), a phase III trial comparing cabozantinib to everolimus in patients with mRCC who have experienced disease progression following treatment with at least one prior VEGFR TKI; CELESTIAL, a phase III trial comparing cabozantinib with placebo in patients with advanced hepatocellular cancer (HCC) who have previously been treated with sorafenib; NSCLC (non-small cell lung cancer); mCRPC (metastatic castration-resistant prostate cancer) and XL888, a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90).